tbuckley/cabot-search huggingface dataset:
S96 Comparative outcomes of outpatient management of primary and secondary spontaneous pneumothorax
Authors: FA Khan, RV Reddy, M Naeem, Y Vali, I Masih, N Siddique
Journal: Thorax (2016)

<h3>Introduction</h3> To compare the effectiveness of ambulatory management of primary (PSP) and selected secondary spontaneous pneumothoraces (SSP) <h3>Methods</h3> Large PSP and selected SSP patients (WHO performance score 0–1) aged between 16–80 presenting between May 2013 and January 2016, were deemed eligible for the ambulatory pathway. They were reassessed every two days with a chest x-ray in the ambulatory care unit. The patients with Pneumostat™ valve (Atrium Medical Corporation) were taught to check for air-leak every day. Patient outcomes and complications were recorded. Patients with tension, iatrogenic or traumatic pneumothorax were excluded from the study. <h3>Primary outcome measure</h3> Success rate at day 5 defined as sustained complete re-expansion of lung with no air leak. <h3>Secondary Outcome measures</h3> Number of days spent with the chest drain in situ. Complications like drain falling out, drain blockage, Infection Number of patients requiring surgical treatment due to persisting air leak. <h3>Results</h3> A total of 110 patients were reviewed with spontaneous pneumothorax, of which 54 were managed on the ambulatory pathway. (Table 1) The pneumothorax resolved successfully in 77% of the primaries pneumothoraces and 67% of the secondaries, with an overall resolution of 72%. In the PSP, five patients (16.7%) went on to have surgery due to non-resolution. Of the 24 SSP, eight (33.3%) patients went on to have surgery due to non-resolution. Complications other than pain were minimal. The mean duration of drainage was 3.8 days in PSP and 5.9 days in SSP. This compares well with the median drainage of 6–8 days for inpatient management of PSP (BTS guidelines).<sup>1</sup> <h3>Conclusion</h3> The success rate was 72% for all spontaneous pneumothorax patients managed almost exclusively as outpatients, which compares well with the 78% suggested in the meta-analysis by Brimms and Maskell.<sup>2</sup> This study confirms that the use of chest drain with one-way valves in the ambulatory management of primary and selected secondary spontaneous pneumothoraces is safe with very few complications. This procedure clearly decreases the number of hospitalisation days and is thus cost saving. <h3>References</h3> Mcduff A. BTS pleural disease guidelines. <i>Thorax</i> 2010;<b>65</b>(Suppl II):ii1–ii76. Brims FJ, Maskell NA. Ambulatory treatment in the management of pneumothorax: a systematic review of the literature. <i>Thorax</i> 2013;<b>68</b>(7):664–9.
A Role of Autotaxin in Non-Mutational Resistance in Imatinib-Resistant Acute Lymphoblastic Leukemia (ALL) Cell Line SupB15RT.
Authors: Aline Schmidt-Tanguy, Annette Romanski, Patricia Mambou, Wolf-Karsten Hofmann, Norbert Ifrah, Oliver G. Ottmann
Journal: Blood (2007)
Selinexor Demonstrates Marked Synergy with Dexamethasone (Sel-Dex) in Preclinical Models and in Patients with Heavily Pretreated Refractory Multiple Myeloma (MM)
Authors: Christine I. Chen, Martin Gutierrez, David S. Siegel, Joshua R. Richter, Nina Wagner-Johnston, Craig C Hofmeister, Jesus G. Berdeja, Nashat Gabrail, Rachid Baz, Morten Mau-Sorensen, Suzanne Trudel, Rodger E. Tiedemann, Vishal Kukreti, Nuchanan Areethamsirikul, Asfar Azmi, Trinayan Kashyap, Yosef Landesman, Tracey Marshall, John McCartney, Jean-Richard Saint-Martin, Sasha Norori, Michael R Savona, Tami Rashal, Robert Carlson, Mansoor R Mirza, Sharon Shacham, Michael Kauffman, Donna E Reece
Journal: Blood (2014)
Identification of a Novel and Efficacious Oral Proteasome Inhibitor As a Potential Clinical Development Candidate
Authors: Kwang-Ai Won, Byung Gyu Kim, Cheol-Kyu Jung, Eok Park, Eunbok Baek, Jonghoon Park, Seung-Wan Kang, Tae Hun Kim, Youngjoo Jung
Journal: Blood (2014)
Widening the Applicability of Human Neutrophil Elastase and Proteinase 3 Peptide Vaccines by Elucidating Immunogenic Non-HLA-A2 MHC Class I Restricted Epitopes.
Authors: Rachel E. Hewitt, J. Joseph Melenhorst, David A. Price, Emma Gostick, Nancy F. Hensel, J.P. McCoy, A. John Barrett
Journal: Blood (2006)
Superior Response Rates for Patients with Myeloid Malignancies Treated with the Combination of Decitabine (DAC) and Arsenic Trioxide (ATO) in a Phase II Adaptive Three Arm Randomization Study: DAC +/- Carboplatin or ATO
Authors: Patricia L. Kropf, Philip A. Pancari, Henry Fung, Hagop M. Kantarjian, Lianchun Xiao, Huang Xuelin, Jean-Pierre Issa
Journal: Blood (2015)
DNA Methylation Changes Following 5-Azacitidine Treatment in Patients with Myelodysplastic Syndrome.
Authors: Huong Thi Thanh Tran, Hee Nam Kim, Yeo-Kyeoung Kim, Jae-Sook Ahn, Il-Kwon Lee, Deok-Hwan Yang, Je-Jung Lee, Hoon Kook, Tai Ju Hwang, Hyeoung-Joon Kim
Journal: Blood (2009)
Colony Stimulating Factor 1 Receptor (CSF1R) As a Potential Novel Therapeutic Target in CLL
Authors: Tyler Sweeney, Stephen E Spurgeon, Jeffrey W. Tyner, Anupriya Agarwal, Hibery Ho, Elie Traer, Patrice Lee, David Chantry, Brian J. Druker, Marc Loriaux
Journal: Blood (2015)
A Randomized Phase II Trial of Fludarabine/Melphalan 140 Vs Fludarabine/ Melphalan 100 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma,
Authors: Muzaffar Qazilbash, Peter F Thall, Ping Liu, Robert Z. Orlowski, Qaiser Bashir, Nina Shah, Partow Kebriaei, Simrit Parmar, Roy Jones, Chitra M Hosing, Uday R Popat, Yvonne T Dinh, Gabriela Rondon, Jatin J Shah, Marcos De Lima, Richard Champlin, Sergio Giralt
Journal: Blood (2011)
IRS2 Is Dowregulated In Primary MDS Cells and During MDS Erythroid Differentiation
Authors: Joao Machado-Neto, Patricia Favaro, Mariana Lazarini, Adriana S S Duarte, Letícia Fröhlich-Archangelo, Fernando Ferreira Costa, Sara T. Olalla-Saad, Fabiola Traina
Journal: Blood (2010)
Clinical Characteristics and Prognostic Factors of Mature T-Cell Lymphomas. A Single Center Experience on 39 Cases.
Authors: Vassiliki I. Pappa, George Mantzios, Christina Economopoulou, Theofanis Economopoulos, Efstathios Papageorgiou, John Dervenoulas, Panagiotis Tsirigotis, Konstantinos Girkas, Maria Katsatou, Sotirios Papageorgiou, Frida Kontsioti, Maria Pappa, Sotirios Raptis
Journal: Blood (2005)
Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study
Authors: Richard R Furman, Herbert A Eradat, Christine G DiRienzo, Craig C Hofmeister, Suzanne R Hayman, John P Leonard, Morton Coleman, Ranjana Advani, Asher Chanan-Khan, Julie Switzky, Qiming M Liao, Damini Shah, Roxanne C Jewell, Steen Lisby, Thomas S Lin
Journal: The Lancet Haematology (2016)
Intersecting Chemical Genomic and Genetic Screens Identifies Glycogen Synthase Kinase-3α (GSK-3α) as a Modulator of Differentiation In Acute Myeloid Leukemia
Authors: Versha Banerji, Kenneth N. Ross, Loretta S. Li, Stacey M. Frumm, Anna C. Schinzel, Cynthia K. Hahn, Rose M. Kakoza, Kwan T. Chow, Linda Ross, Haig Inguilizian, Ilene Galinsky, Richard M Stone, Daniel J DeAngelo, William C. Hahn, Andrew L. Kung, Kimberly Stegmaier
Journal: Blood (2010)
The Spanish Gaucher Registry. An Observatoire To Detect Neurological Manifestations in Patients and Relatives.
Authors: Pilar Giraldo, Pilar Alfonso, Paz Latre, Angeles M. Fernandez-Galan, Dora Alonso, Angeles M. Ruiz, Ana Vasco, Luis Masana, Pilar Leon, Jose L. Guzman, Pablo Sanjurjo, Jesus M. Hernandez-Rivas, Jose Albadalejo, Ines Loyola, Elena Martin-Hernandez, Miguel Pocovi
Journal: Blood (2006)
Total Therapy 2 (TT2) for Multiple Myeloma (MM): Contributions to Survival Outcomes of Dosing of Thalidomide (T), Dexamethasone (D) and Interferon (I) Maintenance Components.
Authors: Frits van Rhee, Bart Barlogie, Jackie Szymonifka, Elias J. Anaissie, Bijay Nair, Sarah Waheed, Yazan Alsayed, Nathan Petty, John Shaughnessy, Antje Hoering, John Crowley
Journal: Blood (2010)
Safety and Efficacy of the mTOR Inhibitor Everolimus as Early Interventional Replacement for Calcineurin Inhibitors In Graft-Versus-Host Disease (GvHD) Prophylaxis After Allogeneic Stem Cell Transplantation
Authors: Herbert G. Sayer, Anne Klink, Thomas Schenk, Anne Treschl, Kristina Schilling, Andreas Hochhaus
Journal: Blood (2010)
Gene-Selective Histone Hyperacetylation and Enhanced Sp1 Occupancy Underpin Transcriptional Modulation of Genes of the Glycolytic-Pentose Phosphate Pathway in Response to Histone Deacetylase Inhibitors - Therapeutic Implications
Authors: Kalliopi Makarona, Valentina Caputo, David Roper, Joana Costa, Gillian Cowan, Aristeidis Chaidos, David O'Connor, Elisabeth Georgiou, Maria Papaioannou, Mark Layton, Irene Roberts, Anastasios Karadimitris
Journal: Blood (2012)
RCP warns over shortage of stroke physicians
Authors: Anne Gulland
Journal: BMJ (2016)

Stroke care has considerably improved in recent years but the shortage of consultants is increasing, a report has warned.

The Royal College of Physicians’ third annual Sentinel Stroke National Audit Programme report showed that, despite stroke care improving year on year, more work is needed to ensure that all patients have access to high quality care regardless of where they live.1

Covering all eligible acute stroke units in England, Wales, and Northern Ireland, the report found that, while the amount of consultant time in stroke care has increased since 2014 (measured in programmed activities), 40% of acute trusts had at least …
Evaluation of IPSS-Revised (IPSS-R) Cytogenetic Risk Stratification and Prognostic Impact of Monosomal Karyotype in 1,014 Patients with Myelodysplastic Syndromes (MDS)
Authors: Naseema Gangat, Mrinal M. Patnaik, Kebede Begna, Taxiarchis Kourelius, Ryan A Knudson, Rhett P Ketterling, Janice M Hodnefield, Curtis A Hanson, Animesh Pardanani, Ayalew Tefferi
Journal: Blood (2012)
Presence of the Killer Immunoglobulin-Like Gene KIR3DS1 Is Associated with Poor Progression Free and Overall Survival Following Autologous Stem Cell Transplantation in Patients with Myeloma.
Authors: Ian H Gabriel, Ruhena Sargent, Hugues de Lavallade, Richard Szydlo, Jane Apperley, Ahmad Khoder, Abdullah Alsuliman, David Marin, Letizia Foroni, John Davis, Chrissy Giles, Edward Kanfer, Amin Rahemtulla, Katayoun Rezvani
Journal: Blood (2009)
Differences in the Spectrum of Anti–Citrullinated Protein Antibody Fine Specificities Between Malaysian and Swedish Patients With Rheumatoid Arthritis: Implications for Disease Pathogenesis
Authors: Chun Lai Too, Shahnaz Murad, Monika Hansson, Linda Mathsson Alm, Jasbir Singh Dhaliwal, Rikard Holmdahl, Per‐Johan Jakobsson, Lars Alfredsson, Lars Klareskog, Johan Rönnelid, Leonid Padyukov
Journal: Arthritis & Rheumatology (2016)

Antibodies to the citrullinated protein antigens (ACPAs) are important in the diagnosis and pathogenesis of rheumatoid arthritis (RA). However, the prevalence of ACPAs with different fine specificities in different populations is unclear. This study sought to examine the fine specificity of the antibody responses toward citrullinated proteins in RA patients from Malaysia, an area where genetic and environmental determinants of RA are different from those in more frequently studied cohorts of Caucasian subjects.A multiplex analytic microarray system was used to analyze the occurrence of antibodies to 10 different citrullinated peptides (filaggrin [fil307-324], vimentin [Vim2-17, Vim60-75], fibrinogen [Fibα563-583, Fibα580-600, Fibβ36-52, Fibβ62-81a, Fibβ62-81b], enolase [Eno5-21], and type II collagen [CitCII355-378]) in serum samples from 4,089 RA patients (1,231 Malaysian and 2,858 Swedish) and 827 healthy control subjects (249 Malaysian and 578 Swedish). The positive reaction threshold for each peptide was set separately for each population based on a specificity of 98%.Distinct differences in the frequencies of 5 ACPA fine specificities (Vim60-75, Vim2-17, Fibβ62-81b, Eno5-21, and CitCII355-378) were found between the Malaysian and Swedish RA populations, despite a nearly identical percentage of patients in each population who were positive for anti-cyclic citrullinated peptide 2 antibodies. In Malaysian RA patients compared with Swedish RA patients, the frequencies of antibodies to Vim60-75 (54% versus 44%, corrected P [Pcorr ] = 1.06 × 10-8 ) and CitCII355-378 (17% versus 13%, Pcorr = 0.02) were significantly higher, while the frequencies of antibodies to Vim2-17 (25% versus 32%, Pcorr = 1.91 × 10-4 ), Fibβ62-81b (15% versus 30%, Pcorr = 2.47 × 10-22 ), and Eno5-21 (23% versus 50%, Pcorr = 3.64 × 10-57 ) were significantly lower.Serum ACPA fine specificities differ between RA patients in different populations, although the total proportions of individuals positive for ACPAs are similar. Differing patterns of ACPA fine specificity could be attributed to variations in genetic and/or environmental factors.
Defect in DNA Double Strand Break Response in Paediatric ALL Is Caused by Upregulation of Multiple Pro-Survival Pathways That Can Serve as Therapeutic Targets.
Authors: Tatjana Stankovic, Eliot Marston, Victoria Weston, Angelo Agathanggelou, Katie Mapp, Pamela Kearns, Francesco Falciani, Paul Moss, Malcolm Taylor
Journal: Blood (2008)
Concordance of ALK rearrangement patterns between CTCs and tumour in non-small cell lung cancer (NSCLC)
Authors: Chye Ling Tan, Wan-Teck Lim, Quan Sing Ng, Tse Hui Lim, Alvin ST. Lim, Daniel SW. Tan, Mei-Kim Ang, Chee-Keong Toh, Takano Angela, Tony KH. Lim
Journal: Annals of Oncology (2015)
The Combination of Lenalidomide and Rituximab Induces Complete and Partial Responses In Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia.
Authors: Alessandra Ferrajoli, Xavier Badoux, Susan O'Brien, William G. Wierda, Stefan Faderl, Zeev Estrov, Manolo Pasia, Susan Lerner, Hagop Kantarjian, Michael J Keating
Journal: Blood (2010)
Factors at Admission That Are Predictive of Increased In-Hospital Bleeding in Acutely Ill Medical Patients: Findings from the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE).
Authors: Hervé Decousus, Rainer B. Zotz, Victor F. Tapson, Beng H. Chong, James B. Froehlich, Ricardo Pavanello, Alex C. Spyropoulos, Manuel Monreal, Gordon FitzGerald, Frederick A. Anderson
Journal: Blood (2005)
Lenalidomide Maintenance Following Non Myeloablative Allogeneic Stem Cell Transplantation In Patients with Multiple Myeloma: Results of the HOVON 76 Study
Authors: Monique C. Minnema, Evelien Kneppers, Ronnie van Der Holt, Marie Jose Kersten, Sonja Zweegman, Ellen Meijer, Edo Vellenga, Tuna Mutis, Petra Cornelisse, Henk Lokhorst
Journal: Blood (2010)
Post-Thaw Viability of Cryopreserved Hematopoietic Progenitor Cell Grafts Influences Patients' Predisposition towards Infectious Complications in the Post-Transplant Period.
Authors: Radovan Vrhovac, Zinaida Peric, Silvana Jurenec, Ika Kardum-Skelin, Biljana Jelic-Puskaric, Zoran Siftar, Jasna Mesaric, Hrvoje Minigo, Branimir Jaksic
Journal: Blood (2009)
Rapid and Semi-Automated Screening of Multiple Samples for Antigen-Specific T Lymphocytes
Authors: Anne Richter, Michaela Niemöller, Inken Verwohl, Katrin Lange, Anna Foerster-Marniok, Olaf Brauns, Sven Kramer, Susanne Höher-Peters, Martin Büscher, Mario Assenmacher, Juergen Schmitz
Journal: Blood (2012)
Hematopoietic Stem Cell Niches Produce Lineage-Instructive Signals to Control Multipotent Progenitor Differentiation
Authors: Ana Cordeiro Gomes, Takahiro Hara, Vivian Y. Lim, Dietmar Herndler-Brandstetter, Erin Nevius, Tatsuki Sugiyama, Shizue Tani-ichi, Susan Schlenner, Ellen Richie, Hans-Reimer Rodewald, Richard A. Flavell, Takashi Nagasawa, Koichi Ikuta, João Pedro Pereira
Journal: Immunity (2016)
The Bruton’s Tyrosine Kinase Inhibitor CC-292 in Diffuse Large B-Cell Lymphoma (DLBCL), T-Cell Lymphoma (TCL), and Hodgkin Lymphoma (HL): Induction of Cell Death and Examination of Rational Novel/Novel Therapeutic Combinations
Authors: Robert A. Cerulli, Ravi Dashnamoorthy, Andrew M. Evens
Journal: Blood (2014)
HFE Genotype Is of Donor Origin and Does Not Correlate with Iron Overload Present in Patients after Allogeneic Stem Cell Transplantation.
Authors: Ann-Kathrin Eisfeld, Ralph Burkhardt, Daniel Teupser, Sabine Schroeder, Rainer Krahl, Andrea Junghans, Elvira Edel, Christa Doehring, Joachim Thiery, Dietger W. Niederwieser, Haifa K. Al-Ali
Journal: Blood (2004)
LNA Anti-MicroRNA-155: A Novel Therapeutic Strategy in Waldenstrom Macroglobulinemia and Chronic Lymphocytic Leukemia
Authors: Yong Zhang, Christopher P. Rombaoa, Aldo M Roccaro, Susanna Obad, Oliver Broom, Stacey M Fernandes, Ranjit Banwait, Yang Liu, Hai T Ngo, Phong Quang, Brittany Morgan, Abdel Kareem Azab, Feda Azab, Patricia Maiso, Michaela Reagan, Antonio Sacco, Erica N Boswell, Sakari Kauppinen, Jennifer R Brown, Irene M. Ghobrial
Journal: Blood (2011)
Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas
Authors: Michelle A. Fanale, Andrei R. Shustov, Andres Forero-Torres, Nancy L. Bartlett, Ranjana H. Advani, Barbara Pro, Robert W. Chen, Andrew Davies, Tim Illidge, Dana A. Kennedy, Steven M. Horwitz
Journal: Blood (2012)
Randomized Comparison of Imatinib with Imatinib Combination Therapies in Newly Diagnosed Chronic Myelogenous Leukemia Patients in Chronic Phase: Design and First Interim Analysis of a Phase III Trial from the French CML Group.
Authors: Agnès Guerci, Franck Nicolini, Frederic Maloisel, Selim Corm, Laurence Legros, Françoise Rigal-Huguet, Philippe Rousselot, Krimo Bouabdallah, Martine Gardembas, Anne Vekoff, Jean-Jacques Kiladjian, Martine Delain, François-Xavier Mahon, Claude Preudhomme, Joelle Guilhot, François Guilhot
Journal: Blood (2005)
Indolent Mantle Cell Lymphoma: A Distinct Subgroup Characterized by Leukemic Phase Disease without Lymphadenopathy.
Authors: Dong Chen, David S. Viswanatha, Clive S. Zent, Tait D. Shanafelt, Timothy G. Call, Neil E. Kay, Daniel L. Van Dyke, Rhett P. Ketterling, Thomas E. Witzig, William G. Morice, Curtis A. Hanson
Journal: Blood (2009)
Smoke-free legislation has potential to reduce the harmful effects of tobacco smoke exposure
Authors: Elida Zairina
Journal: European Respiratory Journal (2016)

T. Faber and colleagues correctly note that the implementation of smoke-free legislation has great potential to reduce the harmful effects of tobacco smoke exposure in children. A smoke-free environment represents P in the MPOWER programme developed by the World Health Organization (WHO) framework convention on tobacco control which aims to control the tobacco epidemic [1]. The acronym MPOWER stands for M: monitor tobacco use and prevention policies; P: protect people from tobacco smoke; O: offer help to quit tobacco smoking; W: warn about the dangers of tobacco; E: enforce bans on tobacco advertising, promotion and sponsorship; and R: raise taxes on tobacco [1]. Data from the WHO shows that in 2015 only 49 countries, with nearly 20% of the world's population, implemented completely policies for a smoke-free environment, thus showing that it is not easy to establish legislative smoking bans in national or even regional settings. Moreover, evidence regarding the effectiveness of legislative smoking bans in public places for reducing harm from second-hand smoke (SHS) exposure is inconclusive. That fact that studies are limited to the nonrandomised controlled trials available in some countries [2] means that more robust evidence is warranted to evaluate the impact of legislation prohibiting smoking in public places, particularly in developing countries. However, it does not mean that it is impossible to conduct such studies-it is possible as long the countries in question have the intention to change! On a different note, raising taxes on cigarettes and other tobacco products shows a reduction in the number of smokers in some countries, including China and France, although more evidence is needed [1]. Lastly, regardless of which programme is most successful in reducing the harmful effects of tobacco, people should realise that protecting pregnant women and children from the harmful effects of SHS exposure is crucial! Smoke–free legislation has potential to reduce the harmful effects of tobacco smoke exposure <http://ow.ly/PumW305Jv1d>
A Core Outcome Set for the Benefits and Adverse Events of Bariatric and Metabolic Surgery: The BARIACT Project
Authors: Karen D. Coulman, James Hopkins, Sara T. Brookes, Katy Chalmers, Barry Main, Amanda Owen-Smith, Robert C. Andrews, James Byrne, Jenny L. Donovan, Graziella Mazza, Barnaby C. Reeves, Chris A. Rogers, Janice L. Thompson, Richard Welbourn, Sarah Wordsworth, Jane M. Blazeby
Journal: PLoS Medicine (2016)

Background Bariatric and metabolic surgery is used as a treatment for patients with severe and complex obesity. However, there is a need to improve outcome selection and reporting in bariatric surgery trials. A Core Outcome Set (COS), an agreed minimum set of outcomes reported in all studies of a specific condition, may achieve this. Here, we present the development of a COS for BARIAtric and metabolic surgery Clinical Trials—the BARIACT Study. Methods and Findings Outcomes identified from systematic reviews and patient interviews informed a questionnaire survey. Patients and health professionals were surveyed three times and asked to rate the importance of each item on a 1–9 scale. Delphi methods provided anonymised feedback to participants. Items not meeting predefined criteria were discarded between rounds. Remaining items were discussed at consensus meetings, held separately with patients and professionals, where the COS was agreed. Data sources identified 2,990 outcomes, which were used to develop a 130-item questionnaire. Round 1 response rates were moderate but subsequently improved to above 75% for other rounds. After rounds 2 and 3, 81 and 14 items were discarded, respectively, leaving 35 items for discussion at consensus meetings. The final COS included nine items: "weight," "diabetes status," "cardiovascular risk," "overall quality of life (QOL)," "mortality," "technical complications of the specific operation," "any re-operation/re-intervention," "dysphagia/regurgitation," and "micronutrient status." The main limitation of this study was that it was based in the United Kingdom only. Conclusions The COS is recommended to be used as a minimum in all trials of bariatric and metabolic surgery. Adoption of the COS will improve data synthesis and the value of research data. Future work will establish methods for the measurement of the outcomes in the COS.
Analyses of Real World Data on Overall Survival in Multiple Myeloma Patients with at Least 3 Prior Lines of Therapy Including a PI and an IMiD, or Double Refractory to a PI and an IMiD
Authors: Saad Usmani, Tahamtan Ahmadi, Yvette Ng, Annette Lam, Ravi Potluri, Maneesha Mehra
Journal: Blood (2015)
Assessment of Frailty Measures and Their Effect on Survival in a Population of Patients Registered At Marche Region Multiple Myeloma (MM) Registry
Authors: Massimo Offidani, Claudia Polloni, Laura Corvatta, Riccardo Centurioni, Giuseppe Visani, Marino Brunori, Silvia Gentili, Massimo Catarini, Arduino Samori, Nicola Blasi, Francesco Alesiani, Patrizia Caraffa, Maurizio Burattini, Piero Galieni, Paolo Fraticelli, Mario Ferranti, Luciano Giuliodori, Pietro Leoni
Journal: Blood (2011)
Alloantigeneic Reactions after Human Hematopoietic Cell Transplantation Induce Genomic Alterations in Epithelium: A Confirmation in Vivo and in Vitro Study and Implications to Secondary Neoplasia
Authors: Maria Themeli, Loizos Petrikkos, Miguel Waterhouse, Hartmut Bertz, Eleni Lagadinou, Nicholas Zoumbos, Jürgen Finke, Alexandros Spyridonidis
Journal: Blood (2008)
Clinical Use of Ultrasound Superb Micro-Vascular Imaging Technique in Patients with Hemophilia Treated with Standard Radiosynovectomy. Initial Report
Authors: Jaroslaw Cwikla, Pawel Laguna, Piotr Zbikowski, Pawel Olejnik, Klukowska Anna, Katarzyna Pawelec, Michal Matysiak
Journal: Blood (2015)